ACR/ARP Meeting Abstracts

This website contains abstracts from upcoming and previous ACR meetings.

Featured Meeting

Chicago skyline

ACR Convergence 2025

October 24-29, 2025
Chicago, Illinois

See meeting details »

There are several ways to explore the abstracts:

Browse abstracts in numerical order.
Browse abstracts by viewing session titles.
View abstracts about a topic by visiting the keyword index.
Search this site for a specific abstract.

Previous Meetings

See abstracts from meetings going back to 2009 on the Meetings Archive page.

Recent Meetings

2025 Late-Breaking Abstracts

Abstract Number: LB01
Low-dose Interleukin-2 Therapy in Systemic Lupus Erythematosus: a double-blind, randomised, placebo-controlled, phase IIb trial
Abstract Number: LB02
Tofacitinib Plus Glucocorticoids Can Effectively Reduce Relapse Rate in IgG4-Related Disease: A Randomized,Open-label controlled Trial
Abstract Number: LB03
Transcutaneous Electrical Nerve Stimulation Effectively Reduces Pain in Fibromyalgia: A Pragmatic Cluster-Randomized Trial Embedded in Physical Therapy Practice
Abstract Number: LB04
Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset and Sustained Drug Free Remission in Refractory Autoimmune Diseases
Abstract Number: LB05
ER Stress-Induced ATP2A3 Drives Rheumatoid Arthritis via Activation of STING Signaling
Abstract Number: LB06
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
Abstract Number: LB07
Adipose-Tissue Derived Mesenchymal Stem Cells vs Hyaluronic Acid in Refractory Knee Osteoarthritis in a low-resource setting: A Phase IIb RCT
Abstract Number: LB08
Efficacy and Safety of Izokibep, a Novel IL-17A Inhibitor, in Patients with Active Psoriatic Arthritis: Week 52 Results from a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2b/3 Study
Abstract Number: LB09
Rotation or Change of Biologic After TNF blocker treatment failure for axial Spondyloarthritis
Abstract Number: LB10
Four-Year Safety and Efficacy of Deucravacitinib in Systemic Lupus Erythematosus: Results From a Phase 2 Program
Abstract Number: LB11
Efficacy and Safety of Telitacicept in Patients with Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study
Abstract Number: LB12
Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial of an Innovative Intra-Articular Apoptotic Cell Therapy in Knee Osteoarthritis (OA): 3-Month Positive Outcomes and Identification of Responder Population (NCT06233474)
Abstract Number: LB13
Obinutuzumab Leads to Deep B-Cell Depletion in the Kidney Parenchyma of Patients With Lupus Nephritis: An Exploratory Analysis of the REGENCY Trial
Abstract Number: LB14
Promising Early Outcomes With BMS-986353, a CD19-directed Chimeric Antigen Receptor T Cell Therapy in Severe Refractory Idiopathic Inflammatory Myopathies: Safety and Efficacy Findings From the Ongoing Phase 1 Trial
Abstract Number: LB15
Dietary Fiber Supplementation Enhances Methotrexate Response and Restores Th17/Treg Balance in Rheumatoid Arthritis: Results from the Superfibre Randomized Trial
Abstract Number: LB16
Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis
Abstract Number: LB17
Circulating biomarkers for organ involvement in systemic lupus erythematosus: a series of systematic reviews and meta-analyses
Abstract Number: LB18
Transcriptomic Signatures of ANA+ and ANA- B Cells Reveal Shifts from Active Disease to Remission in Systemic Lupus Erythematosus
Abstract Number: LB19
Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial
Abstract Number: LB20
Efficacy and Safety of Deucravacitinib up to Week 52: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs
Abstract Number: LB21
IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation
Abstract Number: LB22
Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency
Abstract Number: LB23
A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy
Abstract Number: LB24
Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren’s disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].